We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Mutation Identified Leading to Mitochondrial Dysfunction and Heart Failure

By LabMedica International staff writers
Posted on 07 Jun 2011
A mutation in the gene that encodes for a protein thought to protect cells from stress-induced mitochondrial dysfunction has been linked to the chain of molecular events leading to heart failure.

Mutations in the PTEN-inducible kinase 1 (PINK1) gene cause one form of autosomal recessive early-onset Parkinson's disease. More...
The mutations cause neurons to be more susceptible to reactive oxygen species (ROS) and more likely to undergo apoptosis.

As oxidative stress with associated mitochondrial dysfunction leads to cardiac dysfunction and heart failure (HF), investigators at the Peter Munk Cardiac Center (Toronto, Canada) elected to examine the role of the PINK1 gene in this process.

After observing that PINK1 protein levels were markedly reduced in end-stage human HF and that PINK1 localized exclusively to the mitochondria, the investigators genetically engineered a line of mice to lack the gene for PINK1.

They reported in the May 23, 2011, online edition of the journal Proceedings of the [US] National Academy of Sciences that PINK1 "knockout" mice developed left ventricular dysfunction and evidence of pathological cardiac hypertrophy as early as two months of age. The knockout mice had greater levels of oxidative stress and impaired mitochondrial function. There were also higher degrees of fibrosis, cardiomyocyte apoptosis, and a reciprocal reduction in capillary density.

"Our research suggests that PINK1 is an important switch that sets off a cascade of events affecting heart cell metabolism," said first author Dr. Phyllis Billia, a heart failure specialist at the Peter Munk Cardiac Center. "This could be one of the inciting events in the development of heart failure. We need to learn more about PINK1 and the other proteins it interacts with at the subcellular level, but if we have identified the inciting event that causes the chain of events leading to failure, research and drug development strategies should be focused in this new area of science."

Related Links:
Peter Munk Cardiac Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
HPV Test
Allplex HPV28 Detection
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.